Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 1b trial of rocbrutinib plus R-CHOP is generating early excitement in the lymphoma space. Among 17 efficacy-evaluable patients with non-GCB DLBCL or mantle cell lymphoma, the combo achieved a 100% overall response rate with no dose-limiting toxicities or treatment-related deaths. Rocbrutinib's unique dual-binding mechanism — targeting both wild-type and mutated BTK — sets it apart from earlier BTK inhibitors that struggled in similar settings.
A new BTK inhibitor is making a strong early impression in B-cell lymphoma. Rocbrutinib (LP-168), paired with the standard R-CHOP chemotherapy regimen, achieved a 100% overall response rate in previously untreated patients with non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) in a phase 1b trial presented at the 2026 ESMO Congress. Crucially, the combination was well tolerated — no dose-limiting toxicities, atrial fibrillation, major bleeding, or treatment-related deaths were reported.
What makes rocbrutinib stand out is its dual-binding mechanism: it binds covalently to wild-type BTK and noncovalently to C481-mutated BTK, potentially overcoming a key resistance pathway. Its high selectivity for BTK also limits off-target effects — a notable advantage over earlier agents like ibrutinib, which ran into toxicity issues in the phase 3 PHOENIX trial when combined with R-CHOP.
By the Numbers:
Why it matters: Prior BTK inhibitor + R-CHOP combinations have largely disappointed in DLBCL, making these early results for rocbrutinib a meaningful signal. If confirmed in larger trials, this dual-binding approach could offer a safer and more effective frontline option for patients with aggressive B-cell lymphomas.
